9-(2,5-d|Dioxo-L-3-amino-1-pyrrolidineacetic acid)-10-deglycine Daptomycin

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: 9-(2,5-d|Dioxo-L-3-amino-1-pyrrolidineacetic acid)-10-deglycine Daptomycin
• 英文别名: 3-[[4-amino-2-[[2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[11-[2-(2-aminophenyl)-2-oxoethyl]-21-(3-aminopropyl)-24-(carboxymethyl)-8-(1-carboxypropan-2-yl)-5-(hydroxymethyl)-14,27-dimethyl-3,6,9,12,16,19,22,25,28,32,33-undecaoxo-13-oxa-1,4,7,10,17,20,23,26,29-nonazabicyclo[28.2.1]tritriacontan-15-yl]amino]-4-oxobutanoic acid
• 化学式: C₇₂H₉₉N₁₇O₂₅
• 分子量: 1602.7
• InChiKey: ORZVJBWXRAJYHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.9
• 重原子数：
  114
• 可旋转键数：
  33
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  673
• 氢给体数：
  20
• 氢受体数：
  27

文献信息

• Liquid formulations of daptomycin
  申请人：XELLIA PHARMACEUTICALS APS

  公开号：US10933019B2

  公开（公告）日：2021-03-02

  The present invention relates to liquid pharmaceutical compositions comprising daptomycin, methods of providing such compositions and the use thereof. Provided herein are formulations comprising daptomycin, one or more polar protic solvents, and mixtures thereof. Formulations according to the present invention can further comprise polar aprotic solvent and/or source of calcium.

  本发明涉及包含达托霉素的液体药物组合物、提供此类组合物的方法及其用途。本发明提供了包含达托霉素、一种或多种极性原生溶剂及其混合物的制剂。根据本发明的制剂可进一步包含极性浊溶剂和/或钙源。
• LIQUID FORMULATIONS OF DAPTOMYCIN
  申请人：XELLIA PHARMACEUTICALS APS

  公开号：US20190240155A1

  公开（公告）日：2019-08-08

  The present invention relates to liquid pharmaceutical compositions comprising daptomycin, methods of providing such compositions and the use thereof. Provided herein are formulations comprising daptomycin, one or more polar protic solvents, and mixtures thereof. Formulations according to the present invention can further comprise polar aprotic solvent and/or source of calcium.
• Daptomycin Aqueous Formulations
  申请人：XELLIA PHARMACEUTICALS APS

  公开号：US20220218784A1

  公开（公告）日：2022-07-14

  The present disclosure is related to providing a stable daptomycin aqueous pharmaceutical formulations as a contrast to the inconvenient and potentially problematic methods of lyophilized drug preparation and administration, wherein the aqueous formulations of daptomycin offer the advantage of ease of handling with a high degree of patient acceptability and compliance.